scholarly article | Q13442814 |
P50 | author | Sagar Lonial | Q66431075 |
Paul G. Richardson | Q87712102 | ||
P2093 | author name string | Jonathan L Kaufman | |
Claire Fabre | |||
P2860 | cites work | Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 |
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple myeloma | Q467635 |
P304 | page(s) | 370-376 | |
P577 | publication date | 2013-06-17 | |
P1433 | published in | Clinical Lymphoma, Myeloma & Leukemia | Q5133774 |
P1476 | title | Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy | |
P478 | volume | 13 |
Q38752460 | Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma |
Q38989789 | Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma |
Q26747768 | Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor |
Q51772922 | Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. |
Q36298507 | Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor |
Q36146330 | Histone Deacetylases in Bone Development and Skeletal Disorders. |
Q38910971 | In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. |
Q64099073 | Management of cardiovascular risk in patients with multiple myeloma |
Q27015931 | Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells |
Q38240941 | Not too little, not too much-just right! (Better ways to give high dose melphalan). |
Q39234159 | Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics |
Q39051716 | Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial |
Q37687419 | Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells |
Q33442923 | Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma |
Q38258197 | Recent advances and future directions in targeting the secretory apparatus in multiple myeloma |
Q38928346 | Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin A on the energy metabolism of breast cancer cells |
Q37199772 | Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat |
Q39379624 | Role of epigenetics-microRNA axis in drug resistance of multiple myeloma |
Q39041783 | Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells. |
Q28075599 | The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis |
Q38400460 | The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. |
Q64059633 | The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma |
Q38815402 | Treatment of MM: Upcoming Novel Therapies |
Q38476564 | miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. |
Search more.